☆ 4.7 Editorial Material

Autoimmunity, Recessive Diseases, and Gene Replacement Therapy

MOLECULAR THERAPY (2010)

Journal

MOLECULAR THERAPY

Volume 18, Issue 12, Pages 2045-2047

Publisher

CELL PRESS

DOI: 10.1038/mt.2010.253

Keywords

-

Categories

Biotechnology & Applied Microbiology Genetics & Heredity Medicine, Research & Experimental

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Chemistry, Multidisciplinary

Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1

Jennifer J. Klein, Nancy C. Baker, Daniel H. Foil, Kimberley M. Zorn, Fabio Urbina, Ana C. Puhl, Sean Ekins

Summary: Rare diseases pose challenges in treatment due to limited resources and patient numbers. Using sialidosis as an example, this study utilized bibliometric and machine learning approaches to identify two potential drug candidates through in vitro testing, demonstrating the feasibility of discovering new molecules for rare disease treatments.

ACS OMEGA (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Therapeutic Approaches in Lysosomal Storage Diseases

Carlos Fernandez-Pereira, Beatriz San Millan-Tejado, Maria Gallardo-Gomez, Tania Perez-Marquez, Marta Alves-Villar, Cristina Melcon-Crespo, Julian Fernandez-Martin, Saida Ortolano

Summary: Lysosomal Storage Diseases are multisystemic disorders caused by genetic variants affecting proteins involved in lysosomal function. Therapeutic approaches such as enzyme replacement therapy, gene therapy, and small molecules have been proposed and are under development. The limitations and future perspectives of these therapeutic strategies are highlighted in this review.

BIOMOLECULES (2021)

Add to Collection

Review Neurosciences

Human stem cell models of polyglutamine diseases: Sources for disease models and cell therapy

Lang He, Zhao Chen, Linliu Peng, Beisha Tang, Hong Jiang

Summary: Polyglutamine diseases are a group of neurodegenerative disorders for which there is currently no effective therapy. Intensive research is being conducted on the pathogenesis and potential treatment strategies. Stem cells offer a valuable resource for studying the mechanisms of these diseases and for potential treatment through cell transplantation.

EXPERIMENTAL NEUROLOGY (2021)

Add to Collection

Article Rheumatology

Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)

Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, Arsene Mekinian, Zahir Amoura, Patrice Cacoub, Divi Cornec, Eric Hachulla, Pierre Quartier, Isabelle Melki, Christophe Richez, Raphaele Seror, Benjamin Terrier, Valerie Devauchelle-Pensec, Julien Henry, Marc Gatfosse, Laurence Bouillet, Emeline Gaigneux, Vincent Andre, Gildas Baulier, Aurelie Saunier, Marie Desmurs, Antoine Poulet, Mathieu Ete, Boris Bienvenu, Marie-Elise Truchetet, Martin Michaud, Claire Larroche, Azeddine Dellal, Amelie Leurs, Sebastien Ottaviani, Hubert Nielly, Guillaume Vial, Roland Jaussaud, Benedicte Rouviere, Pierre-Yves Jeandel, Aurelien Guffroy, Anne-Sophie Korganow, Mathieu Jouvray, Alain Meyer, Emmanuel Chatelus, Christelle Sordet, Renaud Felten, Jean Sibilia, Samira Litim-Ahmed-Yahia, Jean-Francois Kleinmann, Xavier Mariette

Summary: This study assessed the tolerance and efficacy of off-label targeted therapies in refractory autoimmune and inflammatory systemic diseases with low prevalence. The results showed that off-label targeted therapies had a corticosteroid-sparing effect and were effective in some patients. However, there were incidences of serious infections and cancer observed, indicating the need for caution in terms of safety.

RMD OPEN (2022)

Add to Collection

Article Genetics & Heredity

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa

Jodi Y. So, Jaron Nazaroff, Chinonso Iwummadu, Nicki Harris, Emily S. Gorell, Shivali Fulchand, Irene Bailey, Daniel McCarthy, Zurab Siprashvili, M. Peter Marinkovich, Jean Y. Tang, Albert S. Chiou

Summary: This Phase 1/2a open-label study evaluated the long-term efficacy and safety of gene-corrected autologous keratinocyte grafts (EB-101) for chronic RDEB wounds. The results showed that treatment with EB-101 appears to be safe and effective, producing long-term improvements in wound healing, pain, and itch for RDEB patients.

ORPHANET JOURNAL OF RARE DISEASES (2022)

Add to Collection

Review Neurosciences

Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review

Lina Palaiodimou, Panagiotis Kokotis, Christina Zompola, Georgia Papagiannopoulou, Eleni Bakola, Marianna Papadopoulou, Vasiliki Zouvelou, Dimitrios Petras, Charalampos Vlachopoulos, Georgios Tsivgoulis

Summary: This narrative review discusses the current and novel therapeutic strategies in Fabry disease (FD), including symptomatic and specific treatments. A multidisciplinary symptomatic treatment is recommended, personalized according to disease manifestations. FD-specific treatments such as enzyme-replacement-therapies and chaperone treatment have been approved, and other treatment options are currently under investigation.

CURRENT NEUROPHARMACOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Heat Shock Protein 90 (Hsp90) and Hsp70 as Potential Therapeutic Targets in Autoimmune Skin Diseases

Stefan Tukaj, Krzysztof Sitko

Summary: Over a hundred different autoimmune diseases have been described to date, affecting various organs including the skin. The loss of immune tolerance in autoimmune diseases leads to chronic inflammation and tissue damage. Current treatments focus on immunosuppression but may cause serious adverse effects. Heat shock proteins Hsp90 and Hsp70 have been identified as potential therapeutic targets for autoimmune skin diseases.

BIOMOLECULES (2022)

Add to Collection

Review Allergy

New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies

Matteo Doglio, Tobias Alexander, Nicoletta Del Papa, John A. Snowden, Raffaella Greco

Summary: Systemic lupus erythematous is a heterogeneous autoimmune disease with a complex etiopathogenesis. Cellular therapies, such as autologous hematopoietic stem cell transplantation and regulatory T-cell therapy, have shown potential for providing more specific and sustainable treatment options for this disease.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Review Cell Biology

Autosomal recessive osteopetrosis: mechanisms and treatments

Sara Penna, Anna Villa, Valentina Capo

Summary: ARO is a severe inherited bone disease with HSCT as the current standard of care, but there are limitations and a need for new therapeutic approaches.

DISEASE MODELS & MECHANISMS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Current Strategies for the Gene Therapy of Autosomal Recessive Congenital Ichthyosis and Other Types of Inherited Ichthyosis

Daria S. Chulpanova, Alisa A. Shaimardanova, Aleksei S. Ponomarev, Somaia Elsheikh, Albert A. Rizvanov, Valeriya V. Solovyeva

Summary: Autosomal recessive congenital ichthyosis (ARCI) is caused by mutations in genes responsible for lipid barrier formation and functioning. Current treatments for ARCI focus on symptomatic relief. Gene and cell therapies show promise in correcting protein activity but are still at an early stage of development.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Medicine, General & Internal

Sarcoidosis: Progression to the chronic stage and pathogenic based treatment (narrative review)

Anna Malkova, Yulia Zinchenko, Anna Starshinova, Dmitriy Kudlay, Igor Kudryavtsev, Anzhela Glushkova, Piotr Yablonskiy, Yehuda Shoenfeld

Summary: This review analyzes the mechanisms and biomarkers of sarcoidosis progression, as well as the pathogenetic basis of sarcoidosis therapy. The characteristics of progressive chronic sarcoidosis and prognostic biomarkers of disease progression are discussed, highlighting the potential use of these biomarkers to determine the group of patients who will benefit from specific treatments.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Gene Therapy for Acquired and Genetic Cholestasis

Javier Martinez-Garcia, Angie Molina, Gloria Gonzalez-Aseguinolaza, Nicholas D. Weber, Cristian Smerdou

Summary: Gene therapy shows promising results in treating cholestatic diseases, but challenges remain in translating this therapy to clinical practice and developing strategies for other types of cholestasis.

BIOMEDICINES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development

Giulia Massaro, Amy F. Geard, Wenfei Liu, Oliver Coombe-Tennant, Simon N. Waddington, Julien Baruteau, Paul Gissen, Ahad A. Rahim

Summary: This study provides a comprehensive overview of the current state of gene therapy in lysosomal diseases, including viral gene delivery vectors, relevant pre-clinical studies, and ongoing clinical trials in recent years.

BIOMOLECULES (2021)

Add to Collection

Editorial Material Multidisciplinary Sciences

The genomic keys to sickle-cell therapy

Ambroise Wonkam

Summary: Despite being the epicentre of sickle-cell disease, Africa is underrepresented in genome-wide association studies.

NATURE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Emerging role of ficolins in autoimmune diseases

Peng Wang, Qian Wu, Zong-Wen Shuai

Summary: Ficolins are pattern-recognition molecules that can trigger complement activation and play a crucial role in various autoimmune diseases. Studies have elucidated the immunological regulations of ficolins and discussed their potential diagnostic and therapeutic applications in autoimmune diseases.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Characterizing Complex Populations of Endogenous Adeno-Associated Viruses by Single-Genome Amplification

Kalyani Nambiar, Qiang Wang, Hanying Yan, James M. Wilson

Summary: Traditional techniques for isolating adeno-associated virus (AAV) genomes from complex samples are not effective, while AAV-SGA technique can isolate, amplify, and sequence AAV genomes individually, providing important tools for constructing gene therapy vectors. In addition, AAV-SGA technique can also study AAV population dynamics and recombination events, enhancing the understanding of virus-host interactions and virus biology.

HUMAN GENE THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses

Joshua J. Sims, Sharon Lian, Rosemary L. Meggersee, Aradhana Kasimsetty, James M. Wilson

Summary: The viral genome of SARS-CoV-2 has rapidly evolved during the COVID-19 pandemic, posing a threat to the efficacy of therapeutic antibodies and vaccines. A decoy inhibitor based on the receptor target of the spike protein shows exceptional binding and neutralizing potency against SARS-CoV-2 variants, providing a strategy to combat the ongoing pandemic and future virus threats.

PLOS ONE (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Neonatal Fc Receptor Inhibition Enables Adeno-Associated Virus Gene Therapy Despite Pre-Existing Humoral Immunity

Makoto Horiuchi, Christian J. J. Hinderer, Hailey N. N. Shankle, Peter M. M. Hayashi, Jessica A. A. Chichester, Casey Kissel, Peter Bell, Cecilia Dyer, James M. M. Wilson

Summary: Advancements in AAV-based gene therapy hold significant potential for treating rare genetic disorders and addressing unmet medical needs. However, the presence of anti-AAV neutralizing antibodies (NAbs) in human populations limits the efficacy of these therapies. By using FcRn-inhibiting monoclonal antibodies, such as M281, pre-existing NAbs can be reduced, allowing for enhanced gene delivery in NAb-positive patients. This study highlights the importance of mitigating humoral immunity to make AAV-based gene therapies effective.

HUMAN GENE THERAPY (2023)

Add to Collection

Article Medicine, Research & Experimental

Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors

Makoto Horiuchi, Christian J. Hinderer, Jenny A. Greig, Cecilia Dyer, Elizabeth L. Buza, Peter Bell, Jessica A. Chichester, Peter M. Hayashi, Hanying Yan, Tamara Goode, James M. Wilson

Summary: Pretreatment with intravenous immunoglobulin can reduce gene transduction to the liver and other peripheral organs, but has no effect on the central nervous system.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Add to Collection

Correction Medicine, Research & Experimental

Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors (vol 27, pg 272, 2022)

Makoto Horiuchi, Christian J. Hinderer, Jenny A. Greig, Cecilia Dyer, Elizabeth L. Buza, Peter Bell, Jessica A. Chichester, Peter M. Hayashi, Hanying Yan, Tamara Goode, James M. Wilson

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Add to Collection

Article Immunology

Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase

Juliette Hordeaux, Ali Ramezani, Steve Tuske, Nickita Mehta, Chunjuan Song, Anna Lynch, Katherine Lupino, Jessica A. Chichester, Elizabeth L. Buza, Cecilia Dyer, Hongwei Yu, Peter Bell, Jill M. Weimer, Hung Do, James M. Wilson

Summary: Immune responses to human non-self transgenes in adeno-associated virus (AAV) gene therapy candidates in nonhuman primates can be challenging. A gene therapy candidate for Pompe disease consisting of AAVhu68 was developed, and some severe adaptive immune responses to the therapy were observed, with variability between animals. Cardiac toxicity was found to be associated with a specific haplotype, and an immunodominant peptide was identified as a potential cause. Additionally, robust and safe gene transfer was achieved in an animal with low pre-existing neutralizing antibodies.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model

Jenny A. Greig, Joanna K. Chorazeczewski, Vivek Chowdhary, Melanie K. Smith, Matthew Jennis, James C. Tarrant, Elizabeth L. Buza, Kimberly Coughlan, Paolo G. V. Martini, James M. Wilson

Summary: Crigler-Najjar syndrome is a rare disorder characterized by hyperbilirubinemia and jaundice caused by UGT1A1 mutations. This study investigated the therapeutic potential of lipid nanoparticle-encapsulated hUGT1A1 mRNA therapy in a mouse model and demonstrated that it can effectively reduce bilirubin levels. The results suggest that this treatment modality may be a potential option for Crigler-Najjar syndrome.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Add to Collection

Article Veterinary Sciences

Adeno-associated virus-vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease

Shelly L. Vaden, Allison R. Kendall, Jonathan D. Foster, Heidi L. New, Jane S. Eagleson, Jacky L. May, Anne M. Traas, Matthew J. Wilson, Beth H. Mcintyre, Christian J. Hinderer, Lauren K. Olenick, James M. Wilson

Summary: The study suggests that SB-001 therapy can effectively treat nonregenerative anemia in cats with CKD, and it is generally well tolerated. However, some cats experienced side effects of hypertension and encephalopathy during the treatment.

JOURNAL OF VETERINARY INTERNAL MEDICINE (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration

Jenny A. Greig, Kelly M. Martins, Camilo Breton, R. Jason Lamontagne, Yanqing Zhu, Zhenning He, John White, Jing-Xu Zhu, Jessica A. Chichester, Qi Zheng, Zhe Zhang, Peter Bell, Lili Wang, James M. Wilson

Summary: Through studying nonhuman primates, we discovered limitations in gene therapy for the liver due to the mechanism of transduction affecting performance. Although transgene expression declines and stabilizes over time, high transduction of non-immunogenic transgenes is still possible. AAV-mediated transgene expression in primate hepatocytes occurs in two phases: high but short-lived expression from episomal genomes, followed by lower but stable expression from integrated vectors.

NATURE BIOTECHNOLOGY (2023)

Add to Collection

Article Biology

Quantification of human mature frataxin protein expression in nonhuman primate hearts after gene therapy

Teerapat Rojsajjakul, Juliette J. Hordeaux, Gourav R. Choudhury, Christian J. Hinderer, Clementina Mesaros, James M. Wilson, Ian A. Blair

Summary: Deficiency in human mature frataxin protein leads to Friedreich's ataxia. Gene therapy, specifically increasing the expression of heart frataxin protein, offers a potential way to prevent early mortality in patients. Using rhesus macaques, researchers tested the pharmacology of a gene therapy treatment and successfully developed a species-specific quantitative method to analyze protein expression in monkey heart tissue.

COMMUNICATIONS BIOLOGY (2023)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Positron Emission Tomography I-124-Labeled AAV Assessment of CSF to Blood Diffusion and Consequent Systemic Distribution of AAV Capsids Following CSF Administration of AAV Vectors

Jonathan B. Rosenberg, Douglas J. Ballon, James Kelly, Edward Fung, Bishnu P. De, Stephen M. Kaminsky, John Babich, Christian Hinderer, Juliette Hordeaux, James M. Wilson, Ronald G. Crystal

MOLECULAR THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Unbiased Screen of the Human Genome for DNA Sequences That Optimize rAAV Transcription in Liver

David J. Steger, Yating Wang, James M. Wilson

MOLECULAR THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

AAV-Meganuclease-Mediated Gene Targeting Achieves Efficient and Sustained Transduction in Newborn and Infant Macaque Liver

Lili Wang, Claude C. Warzecha, Katrina M. Ralph, Peter Bell, John White, Jessica A. Chichester, Ilayaraja Muthuramu, Camilo Breton, Xin Huang, Kirsten Copren, Zhenning He, Hong Zhang, Yanqing Zhu, Kathryn Shelton, Luke J. Segura, Sarah Kezar, Rick A. Finch, Cecilia D. Dyer, James M. Wilson

MOLECULAR THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Generation of Efficient Lipid Nanoparticles for Liver-Directed Gene Therapy and Genome Editing

Claude C. Warzecha, Rakan El-Mayta, Lulu Xue, Lili Wang, Michael J. Mitchell, James M. Wilson

MOLECULAR THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Gene Therapy Candidate Restores Dopamine Levels in Lesch-Nyhan Syndrome

Eileen Workman, Mariya Kostiv, Julia Johansson, Christian Hinderer, James M. Wilson

MOLECULAR THERAPY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.